William Skelly - Acura Pharmaceuticals Independent Director

ACURDelisted Stock  USD 0.05  0.00  0.00%   

Director

Mr. William G. Skelly serves as an Independent Director of Acura Pharmaceutical Technologies, Inc. Since May 1996 and served as our Chairman from October 1996 through June 2000. Since 1990, Mr. Skelly has served as Chairman, President and Chief Executive Officer of Central Biomedia, Inc. and its subsidiary SERA, Inc. From 1985 to 1990, Mr. Skelly served as President of Martec Pharmaceutical, Inc since 2000.
Age 66
Tenure 24 years
Phone847 705 7709
Webhttps://www.acurapharm.com
Skelly earned a Bachelor of Arts degree from Michigan State University and a Masters of Business Administration from the University of MissouriKansas City.

Acura Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3842) % which means that it has lost $0.3842 on every $100 spent on assets. This is way below average. Acura Pharmaceuticals' management efficiency ratios could be used to measure how well Acura Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 105 K in liabilities with Debt to Equity (D/E) ratio of 2.4, implying the company greatly relies on financing operations through barrowing. Acura Pharmaceuticals has a current ratio of 0.84, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Acura Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acura Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acura Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acura to invest in growth at high rates of return. When we think about Acura Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

DIRECTOR Age

Michal VotrubaMYnd Analytics
52
John PappajohnMYnd Analytics
89
Peter UnanueMYnd Analytics
50
Stephen AppelVisionary Education Technology
64
Zachary McadooMYnd Analytics
42
Harvey EadsVisionary Education Technology
73
Danforth LeitnerVisionary Education Technology
78
David BicksVisionary Education Technology
86
Robin SmithMYnd Analytics
53
Andrew SassineMYnd Analytics
51
Geoffrey HarrisMYnd Analytics
55
John FazziniVisionary Education Technology
75
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 12 people. Acura Pharmaceuticals [ACUR] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Acura Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Acura Pharmaceuticals Leadership Team

Elected by the shareholders, the Acura Pharmaceuticals' board of directors comprises two types of representatives: Acura Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acura. The board's role is to monitor Acura Pharmaceuticals' management team and ensure that shareholders' interests are well served. Acura Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acura Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
George Ross, Independent Director
Robert Jones, CEO and President and Director
Bruce Wesson, Independent Director
Mr CPA, Treasurer VP
Peter Clemens, CFO, Principal Accounting Officer, Sr. VP and Secretary
Albert Brzeczko, VP of Technical Affairs
Immanuel Thangaraj, Independent Director
James Emigh, Vice President - Corporate Development
Robert Seiser, VP, Treasurer and Corporate Controller
Bradley Rivet, VP of Marketing
William Skelly, Independent Director

Acura Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Acura Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Acura Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acura Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acura Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Acura Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acura Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acura Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acura Pharmaceuticals to buy it.
The correlation of Acura Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acura Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acura Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acura Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Acura OTC Stock

If you are still planning to invest in Acura Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acura Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Global Correlations
Find global opportunities by holding instruments from different markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Valuation
Check real value of public entities based on technical and fundamental data